However, in some cases, urinary symptoms may have a notable impact on day-to-day life. Experts recommend that people who experience any symptoms of BPH speak with a healthcare professional. Learn more about the latest treatments for an enlarged prostate.
It’s important to note that testosterone and prostate health have been studied for many years, but new research continues to come out. Because of this, doctors and patients have long wondered whether giving testosterone to men with or at risk of BPH might make the condition worse. This treatment can help bring testosterone levels back to normal, and many men report feeling more energetic, focused, and stronger when they use TRT. These symptoms are often linked to low testosterone levels.
Undiagnosed prostate cancer is a significant risk, and TRT could accelerate its progression. Men considering TRT should have open and honest conversations with their doctor about their prostate health and any family history of prostate cancer. However, it’s crucially important to emphasize that TRT can potentially stimulate the growth of existing prostate cancer. One common misconception is that TRT automatically leads to prostate cancer. This means that if a man has undiagnosed prostate cancer, TRT could potentially accelerate its growth. Testosterone replacement therapy (TRT) is a medical treatment designed to restore testosterone levels in men experiencing hypogonadism, a condition characterized by abnormally low testosterone. This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost.
The focused history should enquire for symptoms of hypogonadism, as well as symptoms that may reveal the presence of metabolic syndrome. The possibility of a significant relationship between testosterone, testosterone replacement and LUTS/BPH mandate the urologist consider these factors when patients are being investigated for LUTS. Compared to matched controls, there was no difference between the two groups in terms of IPSS, Qmax, PVR or prostate size. The concept, therefore, that treatment with TRT of hypogonadal males with metabolic syndrome might lead to improvement/stabilization of their LUTS, appears to be confirmed in recent work by Francomano et al.44 They published data in which 20 obese, hypogonadal men with metabolic syndrome were treated with TRT and followed for 5 years. Park et al.38 investigated a group of 1224 otherwise healthy police officers, 29% of whom were diagnosed with metabolic syndrome.
Cancer cases with localized tumors (T1 or T2), no spread (N0 and M0), Gleason grade group 1, and PSA less than 10 ng/mL are designated stage I. The AJCC then combines the TNM scores, Gleason grade group, and results of the PSA blood test to categorize cancer cases into one of four stages, and their subdivisions. T3 is for tumors that grow beyond the prostate – T3a for tumors with any extension outside the prostate; T3b for tumors that invade the adjacent seminal vesicles. Prostate cancer is typically staged using the American Joint Committee on Cancer's (AJCC) three-component TNM system, with scores assigned for the extent of the tumor (T), spread to any lymph nodes (N), and the presence of metastases (M). The extent of cancer spread is assessed by MRI or PSMA scan – a positron emission tomography (PET) imaging technique where a radioactive label that binds the prostate protein prostate-specific membrane antigen is used to detect metastases distant from the prostate.

Gender: Female

Social links